Clinical Pipeline
Beyond stroke
Stroke motor rehabilitation is our lead indication, but the Brain Interchange technology was never built for a single condition. Closed-loop neurotherapy rests on one capability: reading neural activity and responding to it in near real time, continuously, inside the body. That challenge is not unique to stroke. It runs through a range of neurological disorders where the brain needs to be both measured and modulated with precision, and over time.
The platform we developed to help restore movement after stroke is, by design, adaptable to those conditions. Extending it is the work ahead of us, pursued one indication at a time, each on its own clinical and regulatory path, each grounded in evidence before it is grounded in promise.
One platform, many indications
Epilepsy
Brain Interchange has the potential to support future closed‑loop approaches for epilepsy. By sensing neural activity in near real time, the system could detect the onset of abnormal patterns and deliver targeted stimulation to help interrupt seizure progression. Such adaptive neuromodulation strategies aim to complement existing therapies and offer more precise control for patients with drug‑resistant epilepsy.
A clinical investigation with the Brain Interchange System in drug-resistant epilepsy is currently being conducted at Mayo Clinic.
Status, active, not recruiting.
Paralysis
For people living with severe paralysis after spinal cord injury, restoring the ability to communicate and to operate everyday digital devices is a path back to independence. Brain Interchange is being investigated as a fully implantable interface designed to read activity from the surface of the brain and translate intended movements into commands for digital devices. By combining continuous sensing with targeted stimulation, this bidirectional approach aims to support communication and device control for people with severe paralysis.
A clinical investigation with the Brain Interchange System is currently being conducted at UMC Utrecht as part of the INTENSE study.
Status, recruiting.
Depression
For treatment-resistant depression, research is moving toward personalized, circuit-level approaches. Brain Interchange may enable future applications in which neural signals related to mood are measured continuously and stimulation is adapted to the individual over time. This bidirectional, read and write approach could support more precise and consistent modulation of mood-relevant networks.
A first-in-human study with the Brain Interchange System in treatment-resistant depression is in planning at the University Hospital Freiburg.
Status, in planning.
What clinicians, researchers and experts say about our platform
"Our research team has a very nice, longstanding collaboration with the CorTec team. […] Collaboration between industry and academia in the BCI space is crucial."
Mariska Van Steensel
Associate Professor UMC Utrecht
Disclaimer: The Brain Interchange System is an investigational device. FDA Breakthrough Device Designations apply to stroke motor rehabilitation and to communication. Statements regarding further indications are forward-looking.
